13F-HR filed by Venrock Adviser, LLC
Venrock Adviser, LLC filed this 13F-HR for the quarter ended 2020-09-30, filed 2020-11-16, with 22 holding rows worth $511,173,000.
- Accession
- 0001104659-20-125774
- Filer
- CIK 1615982
- Filed
- 2020-11-16
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q3 2020
A holdings report, 22 entries on the cover page, a total value of $511,173,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $511,173,000 with VALUE read as thousands by filing date, 13F file number 028-20281. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| TRILLIUM THERAPEUTICS INC COM NEW | 89620X506 | Stock | 7,204,577 | $102,377,000 | thousands by filing date | |
| CONSTELLATION PHARMACEUTICALS INC. | 210373106 | Common Stock | 4,016,873 | $81,382,000 | thousands by filing date | |
| ALTIMMUNE INC | 02155H200 | COM NEW | 4,500,000 | $59,400,000 | thousands by filing date | |
| ATHIRA PHARMA INC | 04746L104 | COM | 1,521,623 | $28,089,000 | thousands by filing date | |
| SURFACE ONCOLOGY INC | 86877M209 | COM | 3,877,895 | $26,757,000 | thousands by filing date | |
| KEROS THERAPEUTICS INC COM | 492327101 | Stock | 672,306 | $25,931,000 | thousands by filing date | |
| RELMADA THERAPEUTICS INC | 75955J402 | COMMON STOCK | 668,440 | $25,147,000 | thousands by filing date | |
| HUMANIGEN INC COM NEW | 444863104 | Stock | 2,332,516 | $24,818,000 | thousands by filing date | |
| CARDIFF ONCOLOGY INC | 14147L108 | COM | 1,271,985 | $18,049,000 | thousands by filing date | |
| IMV INC | 44974L103 | COM | 4,000,000 | $17,760,000 | thousands by filing date | |
| KURA ONCOLOGY INC COM | 50127T109 | Stock | 575,000 | $17,618,000 | thousands by filing date | |
| MARINUS PHARMACEUTICALS INC | 56854Q101 | COM | 1,192,883 | $15,329,000 | thousands by filing date | |
| CELLDEX THERAPEUTICS INC NEW | 15117B202 | COM NEW | 800,000 | $11,864,000 | thousands by filing date | |
| METACRINE INC | 59101E103 | COM | 1,143,673 | $11,677,000 | thousands by filing date | |
| ALX ONCOLOGY HOLDINGS INC | 00166B105 | COMMON STOCK | 300,000 | $11,322,000 | thousands by filing date | |
| COGENT BIOSCIENCES INC COM | 903214104 | COM | 4,355,273 | $10,191,000 | thousands by filing date | |
| SYNDAX PHARMACEUTICALS INC | 87164F105 | COM | 625,710 | $9,235,000 | thousands by filing date | |
| FS DEV CORP | 303020101 | COM CL A | 500,000 | $5,599,000 | thousands by filing date | |
| BCTG ACQUISITION CORP | 05492W103 | COM | 500,000 | $5,180,000 | thousands by filing date | |
| TAYSHA GENE THERAPIES INC | 877619106 | COMMON STOCK | 107,982 | $2,598,000 | thousands by filing date | |
| GALERA THERAPEUTICS EQUICLASS EQUITY | 36338D108 | COMMON STOCK | 51,653 | $467,000 | thousands by filing date | |
| MEDICENNA THERAPEUTICS F | 58490H107 | FOREIGN CANADIAN | 92,453 | $383,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001104659-20-125774 | this filing | 2020-11-16 | acceptance time not in the bulk data set |